



### Product Portfolio

Product	Dosage Form   Strength	Reference Product	Basic Patent/ Regulatory Protection		Dossier Status
			EU*	US	
 <b>Alimentary Tract and Metabolism</b>					
<b>Prucalopride</b>	tabs.   <b>1mg, 2mg</b>	Resolor®   Motegrity®	-	-	Dossier Ready 
<b>Sitagliptin</b>	tabs.   <b>25mg, 50mg, 100mg</b>	Januvia®	-	-	Dossier Ready/Approved 
<b>Sitagliptin + Metformin</b>	tabs.   <b>50+50mg, 50+500mg, 50+1000mg</b>	Janumet®	-	-	Dossier Ready/Approved 
<b>Vildagliptin</b>	tabs.   <b>50mg</b>	Galvus®	-	-	Dossier Ready/Approved 
<b>Vildagliptin + Metformin</b>	f.c. tabs.   <b>50+500mg, 50+850mg, 50+1000mg</b>	Eucreas®	-	-	Dossier Ready/Approved 
 <b>Anti-infectives for Systemic Use</b>					
<b>Azithromycin</b>	f.c. tabs.   <b>250mg, 500mg, 600mg</b>	Zithromax®	-	-	Dossier Ready/Approved 
<b>Valganciclovir</b>	f.c. tabs.   <b>450mg</b>	Valcyte®	-	-	Dossier Ready/Approved 
 <b>Antineoplastic and Immunomodulating Agents</b>					
<b>Abiraterone</b> <small>ONConcept</small>	tabs.   <b>250mg</b>	Zytiga®	-	-	Dossier Ready/Approved 
<b>Abiraterone</b> <small>ONConcept</small>	f.c. tabs.   <b>500mg</b>	Zytiga®	-	-	Dossier Ready/Approved 
<b>Cabozantinib</b> <small>ONConcept</small>	f.c. tabs.   <b>20mg, 40mg, 60mg</b>	Cabometyx®	09/2029 (PED <sup>1</sup> )	09/2028 (ME)	Under Development 
<b>Enzalutamide</b> <small>ONConcept</small>	f.c. tabs.   <b>40mg, 80mg, 120mg, 180mg</b>	Xtandi®	06/2028 (SPC)	08/2027 (PAT)	Under Development 
<b>Fingolimod</b> <small>ONConcept</small>	caps.   <b>0,25mg<sup>2</sup>, 0.5mg</b>	Gilenya®	-	-	Dossier Ready/Approved 
<b>Ibrutinib</b> <small>ONConcept</small>	f.c. tabs.   <b>140mg, 280mg, 420mg, 560mg</b>	Imbruvica®	04/2030 (PED <sup>1</sup> )	05/2028 (PED)	Under Development 
<b>Lenvatinib</b> <small>ONConcept</small>	caps.   <b>4mg, 10mg</b>	Kisplyx®   Lenvima®	04/2027 (PED <sup>1</sup> )	04/2026 (PED <sup>1</sup> )	Under Development 
<b>Nilotinib</b> <small>ONConcept</small>	caps.   <b>50mg, 150mg, 200mg</b>	Tasigna®	-	01/2024 (PED)	Under Development 
<b>Olaparib</b> <small>ONConcept</small>	f.c. tabs.   <b>100mg, 150mg</b>	Lynparza®	09/2029 (PED <sup>1</sup> )	04/2028 (PTE)	Under Development 
<b>Palbociclib</b> <small>ONConcept</small>	tabs.   <b>75mg, 100mg, 125mg</b>	Ibrance®	07/2028 (PED)	09/2027 (PED)	Under Development 

CPP | MA availability upon request. \* Germany used as reference. <sup>1</sup> – Pending. <sup>2</sup> – Upon request.

ME – Market exclusivity. PAT – Patent. PED – Pediatric Exclusivity. PTE – Patent Term Extension. SPC – Supplementary Protection Certificate.

**ONConcept®** – Partnership between Bluepharma, Helm and Welding.

Bluepharma's facilities are EU-GMP certified and approved by US FDA (2009, 2012, 2014, 2016, 2019), SFDA (Kingdom of Saudi Arabia), ANVISA (Brazil), MFDS (Republic of Korea), Minpromtorg (Russian Federation), MOH Libya and by TMMDA (Turkey).

We are registered in Iraq, Taiwan, Jordan, UAE, Kurdistan and Vietnam.



Create value through **Innovation**.  
How? Contact us!
















For business inquiries: [business@bluepharma.pt](mailto:business@bluepharma.pt)  
S. Martinho do Bispo · 3045-016 Coimbra · PORTUGAL

[www.bluepharmagroup.com](http://www.bluepharmagroup.com)

scan me  
CRDMO Services



## Product Portfolio

Product	Dosage Form   Strength	Reference Product	Basic Patent/ Regulatory Protection		Dossier Status
			EU*	US	
<b>Antineoplastic and Immunomodulating Agents</b>					
<b>Palbociclib</b> <small>ONConcept</small>	caps.   <b>75mg, 100mg, 125mg</b>	Ibrance®	07/2028 (PED)	09/2027 (PED)	Dossier Ready 
<b>Pomalidomide</b> <small>ONConcept</small>	caps.   <b>1mg, 2mg, 3mg, 4mg</b>	Imnovid®   Pomalyst®	-	-	Dossier Ready 
<b>Pazopanib</b> <small>ONConcept</small>	f.c. caps.   <b>200mg, 400mg</b>	Votrient®	12/2025 (PED)	-	Dossier Ready 
<b>Ruxolitinib</b> <small>ONConcept</small>	f.c. tabs.   <b>5mg, 10mg, 15mg, 20mg, 25mg</b>	Jakavi®   Jakafi®	-	-	Under Development 
<b>Sunitinib</b> <small>ONConcept</small>	caps.   <b>12.5mg, 25mg, 37.5mg, 50mg</b>	Sutent®	-	-	Dossier Ready/Approved 
<b>Tofacitinib IR</b> <small>ONConcept</small>	f.c. tabs.   <b>5mg, 10mg</b>	Xeljanz®	03/2028 (ME)	06/2026 (PED)	Dossier Ready/Approved 
<b>Tofacitinib XR</b> <small>ONConcept</small>	e.r. tabs.   <b>11mg, 22mg</b>	Xeljanz XR®	03/2028 (ME)	06/2026 (PED)	Under Development 
<b>Blood and Blood Forming Organs</b>					
<b>Eltrombopag</b> <small>ONConcept</small>	f.c. tabs.   <b>12.5mg, 25mg, 50mg, 75mg</b>	Revolade®   Promacta®	09/2025 (PED)	-	Under Development 
<b>Rivaroxaban</b>	f.c. tabs.   <b>2.5mg, 10mg, 15mg, 20mg</b>	Xarelto®	04/2024 (PED)	02/2025 (PED)	Dossier Ready/Approved 
<b>Cardiovascular System</b>					
<b>Amlodipine</b>	tabs.   <b>5mg, 10mg</b>	Norvasc®	-	-	Dossier Ready/Approved 
<b>Ephedrine</b>	injection   <b>50mg/mL</b>	Akovaz®	-	-	Dossier Ready/Approved 
<b>Musculo-skeletal System</b>					
<b>Febuxostat</b>	f.c. tabs.   <b>80mg, 120mg</b>	Adenuric®   Uloric®	-	-	Dossier Ready/Approved 
<b>Penicillamine</b>	caps.   <b>250mg</b>	Cuprimine®	-	-	Dossier Ready/Approved 
<b>Nervous System</b>					
<b>Alprazolam</b>	tabs.   <b>0.25mg, 0.5mg, 1mg</b>	Xanax®	-	-	Dossier Ready/Approved 
<b>Paroxetine</b>	f.c. tabs.   <b>20mg</b>	Seroxat®   Paxil®	-	-	Dossier Ready/Approved 

CPP | MA availability upon request. \* Germany used as reference. <sup>1</sup> – Pending. <sup>2</sup> – Upon request.

ME – Market exclusivity. PAT – Patent. PED – Pediatric Exclusivity. PTE – Patent Term Extension. SPC – Supplementary Protection Certificate.

ONConcept® – Partnership between Bluepharma, Helm and Welding.

Bluepharma's facilities are EU-GMP certified and approved by US FDA (2009, 2012, 2014, 2016, 2019), SFDA (Kingdom of Saudi Arabia), ANVISA (Brazil), MFDS (Republic of Korea), Minpromtorg (Russian Federation), MOH Libya and by TMMDA (Turkey).

We are registered in Iraq, Taiwan, Jordan, UAE, Kurdistan and Vietnam.



Create value through **Innovation**.  
How? Contact us!







For business inquiries: [business@bluepharma.pt](mailto:business@bluepharma.pt)  
S. Martinho do Bispo · 3045-016 Coimbra · PORTUGAL

[www.bluepharmagroup.com](http://www.bluepharmagroup.com)





## Other Available Dossiers

Product	Dosage Form   Strength	Reference Product
 <b>Alimentary Tract and Metabolism</b>		
<b>Acarbose</b>	tabs.   <b>50mg, 100mg</b>	Glucobay®
 <b>Anti-infectives for Systemic Use</b>		
<b>Ciprofloxacin</b>	f.c. tabs.   <b>250mg, 500mg, 750mg</b>	Ciproxin®   Cipro®
<b>Clarithromycin</b>	f.c. tabs.   <b>250mg, 500mg</b>	Klaricid®   Biaxin®
<b>Moxifloxacin</b>	f.c. tabs.   <b>400mg</b>	Avelox®
 <b>Blood and Blood Forming Organs</b>		
<b>Clopidogrel</b>	tabs.   <b>75mg</b>	Plavix®
 <b>Cardiovascular System</b>		
<b>Candesartan</b>	tabs.   <b>4mg, 8mg, 16mg, 32mg</b>	Blopress®   Atacand®
<b>Candesartan HCTZ</b>	tabs.   <b>8+12.5mg, 16+12.5mg</b>	Blopress Plus®   Atacand HCT®
<b>Droxidopa</b>	caps.   <b>100mg, 200mg, 300mg</b>	Nothera®
<b>Ezetimibe + Simvastatin</b>	tabs.   <b>10+20mg, 10+40mg, 10+80mg</b>	Vytorin®   Inegy®
<b>Irbesartan</b>	f.c. tabs.   <b>75mg, 150mg, 300mg</b>	Approvel®   Avapro®
<b>Irbesartan HCTZ</b>	f.c. tabs.   <b>150+12.5mg, 300+12.5mg, 300+25mg</b>	Coapprovel®   Avalide®
<b>Losartan</b>	f.c. tabs.   <b>12.5mg, 25mg, 50mg, 100mg</b>	Cozaar®
<b>Losartan HCTZ</b>	f.c. tabs.   <b>50+12.5mg, 100+25mg</b>	Cozaar Plus®
 <b>Musculo-skeletal System</b>		
<b>Nimesulide</b>	tabs.   <b>100mg</b>	Aulin®   Nimed®
 <b>Nervous System</b>		
<b>Clonidine ER</b>	tabs.   <b>0.1mg</b>	Kapvay®
<b>Levetiracetam</b>	tabs.   <b>250mg, 500mg, 750mg, 1000mg</b>	Keppra®
<b>Levetiracetam</b>	oral solution   <b>100mg/mL</b>	Keppra®

CPP | MA availability upon request. \* Germany used as reference. <sup>1</sup> - Pending. <sup>2</sup> - Upon request.

ME - Market exclusivity. PAT - Patent. PED - Pediatric Exclusivity. PTE - Patent Term Extension. SPC - Supplementary Protection Certificate.

ONConcept® - Partnership between Bluepharma, Helm and Welding.

Bluepharma's facilities are EU-GMP certified and approved by US FDA (2009, 2012, 2014, 2016, 2019), SFDA (Kingdom of Saudi Arabia), ANVISA (Brazil), MFDS (Republic of Korea), Minpromtorg (Russian Federation), MOH Libya and by TMMDA (Turkey).

We are registered in Iraq, Taiwan, Jordan, UAE, Kurdistan and Vietnam.



Create value through **Innovation**.  
How? Contact us!

For business inquiries: [business@bluepharma.pt](mailto:business@bluepharma.pt)  
S. Martinho do Bispo · 3045-016 Coimbra · PORTUGAL

[www.bluepharmagroup.com](http://www.bluepharmagroup.com)





# PRODUCT PORTFOLIO








Development and Licensing Opportunities

your partner  
that cares

## Complex Generics

Product	Dosage Form   Strength	Reference Product	Indication	Dossier Status
 <b>Injectable</b>				
<b>Amphotericin B</b>	liposome injection   50mg/vial	Ambisome®	Fungal infections	Upon Request
<b>Bupivacaine</b>	liposome injection   13.3mg/mL	Exparel®	Postsurgical Analgesia	Upon Request
<b>Buprenorphine + Naloxone</b>	sublingual film   2+0,5mg, 4+1mg, 8+2mg, 12+3mg	Suboxone®	Opioid Dependence	Upon Request
<b>Daunorubicin + Cytarabine</b>	liposome injection   44mg+100mg/vial	Vyxeos®	Oncology	Upon Request
<b>Doxorubicin</b>	liposome injection   2mg/mL	Caelyx®   Doxil®	Oncology	Upon Request
<b>Irinotecan</b>	liposome injection   4.3mg/mL	Onivyde®	Oncology	Upon Request
 <b>Nasal</b>				
<b>Dihydroergotamine</b>	nasal spray   4mg/ml	Migranal®	Migraine	Available

## Value Added Medicines

Product	Dosage Form	Indication	Status
<b>Fixed-dose Combinations</b>			
<b>Ramipril + Amlodipine + Atorvastatin</b>	Tablets	Hypertension/Dyslipidemia	Available 
<b>Candesartan + Amlodipine + Atorvastatin</b>	Tablets	Hypertension/Dyslipidemia	Available 
Other Fixed-dose Combinations available upon request.			
<b>Oromucosal Delivery</b>			
<b>BlueOS02</b>	Oral Thin Films	Multiple Sclerosis	Upon Request 
<b>BluEase04</b>	Buccal Spray	Oral Mucositis	Upon Request 
<b>Blue086</b>	Oral Dispersible Tablet	Migraine	Upon Request 
<b>Oromucosal Delivery</b>			
<b>BlueCI01</b>	Liposome Injection	Rheumatoid Arthritis	Upon Request 
<b>PEGASEMP™</b>	Liposome Injection	Oncology	Upon Request 

CPP | MA availability upon request. \* Germany used as reference. <sup>1</sup> - Pending. <sup>2</sup> - Upon request.

ME - Market exclusivity. PAT - Patent. PED - Pediatric Exclusivity. PTE - Patent Term Extension. SPC - Supplementary Protection Certificate.

ONConcept® - Partnership between Bluepharma, Helm and Welding.

Bluepharma's facilities are EU-GMP certified and approved by US FDA (2009, 2012, 2014, 2016, 2019), SFDA (Kingdom of Saudi Arabia), ANVISA (Brazil), MFDS (Republic of Korea), Minpromtorg (Russian Federation), MOH Libya and by TMMDA (Turkey).

We are registered in Iraq, Taiwan, Jordan, UAE, Kurdistan and Vietnam.



Create value through Innovation.  
How? Contact us!

For business inquiries: [business@bluepharma.pt](mailto:business@bluepharma.pt)  
S. Martinho do Bispo · 3045-016 Coimbra · PORTUGAL

[www.bluepharmagroup.com](http://www.bluepharmagroup.com)

scan me  
CRDMO Services

